Few questions regarding the use of Mdivi-1 for mitochondrial autophagy inhibition in C57BL/6 mice:
I plan to use Mdivi-1 to inhibit mitochondrial autophagy in C57BL/6 mice, but I couldn’t find literature with specific dosing schedules, concentrations, or administration routes. Could anyone share a suitable dosing protocol?
Before Mdivi-1 treatment, I will use MPTP at 25 mg/kg by intraperitoneal injection for 7 days to establish a Parkinson’s disease model in C57BL/6 mice. Would the combination of these two drugs increase the mortality risk in mice?
When inhibiting mitochondrial autophagy with Mdivi-1, is there a possibility of spontaneous recovery? If we intervene for 2 weeks after Mdivi-1 administration, could the suppressed mitochondrial autophagy function recover after those 2 weeks?
We usually search with the keywords "Mdivi-1 mg/kg mitophagy mice" on Google Scholar or Google. A comprehensive summary of various dosing regimens can be found in PMID: 35002619 (see the figure). Additional relevant studies: PMID: 38612835 and PMID: 31205936.
For combined use with MPTP, consider both the additive toxicity of the doses and the tolerance of the mice. I recommend testing different high- and low-dose groups first to determine safe conditions. A similar combined-use study can be found in PMID: 25370169.
Mdivi-1 has a relatively short half-life, so after 2 weeks, it’s quite possible that its effect will no longer be present. One study (PMID: 31324254) reports a half-life of approximately 12 hours.
The answer to this question comes from MedChemExpress Technical Support.